|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |||||||||||
| 化学式 | C22H22N6O3 |
||||||||||||||
| 分子量 | 418.45 | CAS No. | 1448169-71-8 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO | 84 mg/mL (200.74 mM) | ||||||||||||
| Water | Insoluble | ||||||||||||||
| Ethanol | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | Futibatinib (TAS-120) is an irreversible fibroblast growth factor receptor (FGFR) inhibitor which inhibits all 4 subtypes of FGFR with enzyme IC50 values of 1.8 nM, 1.4 nM, 1.6 nM and 3.7 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
|---|---|
| in vitro | Futibatinib (TAS-120) is an irreversible fibroblast growth factor receptor (FGFR) inhibitor which inhibits all 4 subtypes of FGFR with enzyme IC50 values of 1.8 nM, 1.4 nM, 1.6 nM and 3.7 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| 細胞アッセイ | 細胞株 | OCUM-2MD3 cells |
|---|---|---|
| 濃度 | ||
| 反応時間 | 1 h | |
| 実験の流れ | Cells were treated with varying concentrations of Futibatinib for 1 hour. |
|
| 動物実験 | 動物モデル | Nude mice |
| 投薬量 | 0.15, 0.5, 1.5, & 5 mg/kg | |
| 投与方法 | p.o. |
|
| Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer [ bioRxiv, 2025, 2025.02.17.638725] | PubMed: 40027618 |
| FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma [ Nat Commun, 2024, 15(1):3805] | PubMed: 38714664 |
| Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies [ Clin Cancer Res, 2024, 10.1158/1078-0432.CCR-24-1834] | PubMed: 39226398 |
| Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3 [ Biomed Pharmacother, 2024, 180:117533] | PubMed: 39405909 |
| iPSC-derived megakaryocytes and platelets accelerate wound healing and angiogenesis [ Stem Cell Res Ther, 2024, 15(1):364] | PubMed: 39402677 |
| Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells [ Breast Cancer Res, 2024, 26(1):54] | PubMed: 38553760 |
| Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
| Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
| Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
| Dietary phosphorus consumption alters T cell populations, cytokine production, and bone volume in mice [ JCI Insight, 2023, 8(10)e154729] | PubMed: 37079375 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。